Predicting the effectiveness of methotrexate therapy based on basal expression of the AMP-activated protein kinase gene in the blood of patients with rheumatoid arthritis ; Прогнозирование эффективности терапии метотрексатом по базальной экспрессии гена АМР-активируемой протеинкиназы в крови больных ревматоидным артритом

Συγγραφείς: E. V. Chetina, N. V. Demidova, G. A. Markova, E. P. Salyanova, Е. В. Четина, Н. В. Демидова, Г. А. Маркова, Е. П. Салянова

Συνεισφορές: The work was carried out with the financial support of the Russian Foundation for Basic Research (project №12-04-00038a)., Работа осуществлена при финансовой поддержке Российского фонда фундаментальных исследований (проект №12-04-00038а).

Πηγή: Modern Rheumatology Journal; Том 16, № 1 (2022); 46-51 ; Современная ревматология; Том 16, № 1 (2022); 46-51 ; 2310-158X ; 1996-7012

Θεματικοί όροι: метотрексат, gene expression, AMP-activated protein kinase gene, peripheral blood, inflammation, joint damage, methotrexate, экспрессия генов, ген АМР-активируемой протеинкиназы, периферическая кровь, воспаление, поражение суставов

Περιγραφή αρχείου: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1251/1207; https://mrj.ima-press.net/mrj/article/view/1251/1208; Harris ED Jr. Rheumatoid Arthritis: pathophysiology and implications for therapy. N Engl J Med. 1990 May 3;322(18):1277-89. doi:10.1056/NEJM199005033221805.; Firenstein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003 May 15;423(6937): 356-61. doi:10.1038/nature01661.; Насонов ЕЛ, редактор. Ревматология: Клинические рекомендации. Москва: ГЕОТАР-Медиа; 2010.; Gossec L, Dougados M, Goupille P, et al. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis. 2004 Jun;63(6):675-80. doi:10.1136/ard.2003.010611.; Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomized, doubleblind, parallel treatment trial. Lancet. 2008 Aug 2;372(9636):375-82. doi:10.1016/S0140-6736(08)61000-4. Epub 2008 Jul 16.; Visser H, le Cessie S, Vos K, et al. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum. 2002 Feb;46(2):357-65. doi:10.1002/art.10117.; Четина ЕВ, Демидова НВ, Каратеев ДЕ и др. Ассоциация экспрессии генов в крови больных ревматоидным артритом с клиническими и лабораторными показателями до и после терапии метотрексатом. Научно-практическая ревматология. 2016;(2):155-63.; Tchetina EV, Demidova NV, Markova GA, et al. Increased baseline RUNX 2, caspase 3, and p21 gene expressions in the peripheral blood of naпve rheumatoid arthritis patients are associated with improved clinical response to methotrexate therapy. Int J Rheum Dis. 2017 Oct;20(10):1468-80. doi:10.1111/1756-185X.13131. Epub 2017 Jul 25.; Sharabi A, Tsokos GC. T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy. Nat Rev Rheumatol. 2020 Feb;16(2):100-12. doi:10.1038/s41584-019-0356-x. Epub 2020 Jan 16.; Finlay DK. N-myristoylation of AMPK controls T cell inflammatory function. Nat Immunol. 2019 Mar;20(3):252-4. doi:10.1038/s41590-019-0322-4.; Shi M, Wang J, Xiao Y, et al. Glycogen Metabolism and Rheumatoid Arthritis: The Role of Glycogen Synthase 1 in Regulation of Synovial Inflammation via Blocking AMP-Activated Protein Kinase Activation. Front Immunol. 2018 Jul 27;9:1714. doi:10.3389/fimmu.2018.01714.eCollection 2018.; Terkeltaub R, Yang B, Lotz M, et al. Chondrocyte AMP-activated protein kinase activity suppresses matrix degradation responses to proinflammatory cytokines interleukin-1 and tumor necrosis factor. Arthritis Rheum.2011 Jul;63(7):1928-37. doi:10.1002/art.30333.; Wen Z, Jin K, Shen Y, et al. N-myristoyltransferase deficiency impairs activation of kinase AMPK and promotes synovial tissue inflammation. Nat Immunol. 2019 Mar;20(3): 313-25. doi:10.1038/s41590-018-0296-7. Epub 2019 Feb 4.; Thornton CC, Al-Rashed F, Calay D, et al. Methotrexate-mediated activation of an AMPK-CREB-dependent pathway: a novel mechanism for vascular protection in chronic systemic inflammation. Ann Rheum Dis. 2016 Feb;75(2):439-48. doi:10.1136/annrheumdis-2014-206305. Epub 2015 Jan 9.; Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar; 31(3):315-24. doi:10.1002/art.1780310302.; Van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 1999 Mar;26(3):743-5.; Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev. 2009 Jul; 89(3):1025-78. doi:10.1152/physrev.00011.2008.; Hardie DG, Ross FA, Hawley SA. AMPactivated protein kinase: a target for drugs both ancient and modern. Chem Biol. 2012 Oct 26;19(10):1222-36. doi:10.1016/j.chembiol.2012.08.019.; Faubert B, Boily G, Izreig S, et al. AMPK Is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab. 2013 Jan 8;17(1):113-24. doi:10.1016/j.cmet.2012.12.001. Epub 2012 Dec 27.; Salt IP, Palmer TM. Exploiting the antiinflammatory effects of AMP-activated protein kinase activation. Expert Opin Investig Drugs. 2012 Aug;21(8):1155-67. doi:10.1517/13543784.2012.696609. Epub 2012 Jun 14.; Sag D, Carling D, Stout RD, et al. Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype.J Immunol. 2008 Dec 15;181(12):8633-41. doi:10.4049/jimmunol.181.12.8633.; Yang Z, Shi H, Xue BZ. Macrophage {alpha}1-AMP-activated protein kinase ({alpha}1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J Biol Chem. 2010 Jun 18;285(25):19051-9. doi:10.1074/jbc.M110.123620. Epub 2010 Apr 26.; Agrawal S, Misra R, Aggarwal A. Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol. 2007 Feb;26(2):201-4. doi:10.1007/s10067-006-0275-5. Epub 2006 Mar 30.; Ермакова ЮА, Каратеев ДЕ, Лучихина ЕЛ, Демидова НВ. Влияние АЦЦПи РФ-позитивности на формирование исходов раннего ревматоилного артрита в длительной перспективе. Саратовский научно-медицинский журнал. 2015;11(2):135-41.

Διαθεσιμότητα: https://mrj.ima-press.net/mrj/article/view/1251
https://doi.org/10.14412/1996-7012-2022-1-46-51

Results of direct comparison of the clinical efficacy of ixekizumab and adalimumab: data from the SPIRIT H2H study ; Результаты прямого сравнения клинической эффективности иксекизумаба и адалимумаба: данные исследования SPIRIT H2H

Συγγραφείς: T. V. Korotaeva, Т. В. Коротаева

Πηγή: Modern Rheumatology Journal; Том 14, № 3 (2020); 50-56 ; Современная ревматология; Том 14, № 3 (2020); 50-56 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2020-3

Θεματικοί όροι: нежелательные явления, psoriasis, ixekizumab, adalimumab, joint damage, biological agents, adverse events, псориаз, иксекизумаб, адалимумаб, поражение суставов, генно-инженерные биологические препараты

Περιγραφή αρχείου: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1046/1007; Kavanaugh A, Gottlieb A, Morita A, et al. The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. Ann Rheum Dis. 2019 Sep;78(9):1215-19. doi:10.1136/annrheumdis-2018-215003. Epub 2019 May 21.; Kavanaugh A, Helliwell P, Ritchlin CT. Psoriatic arthritis and burden of disease: patient perspectives from the populationbased multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Rheumatol Ther. 2016 Jun;3(1):91-102. doi:10.1007/s40744-016-0029-z. Epub 2016 Feb 29.; Singh JA, Guyatt G, Ogdie A, et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Care Res (Hoboken). 2019 Jan;71(1):2-29. doi:10.1002/acr.23789. Epub 2018 Nov 30.; Kerschbaumer A, Smolen J, Dougados M, et al. Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2020 Jun;79(6):778-86. doi:10.1136/annrheumdis-2020-217163. Epub 2020 May 7.; Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016 May;68(5):1060-71. doi:10.1002/art.39573. Epub 2016 Mar 23.; Zisapel M, Zisman D, Madar-Balakirski N, et al. Prevalence of TNF-α blocker immunogenicity in psoriatic arthritis. J Rheumatol. 2015 Jan;42(1):73-8. doi:10.3899/jrheum.140685. Epub 2014 Nov 15.; Vogelzang EH, Kneepkens EL, Nurmohamed MT, et al. Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up. Ann Rheum Dis. 2014 Dec;73(12):2178-82. doi:10.1136/annrheumdis-2014-205554. Epub 2014 Aug 12.; Mease P, Collier D, Saunders K, et al. Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the CORRONA registry. RMD Open. 2015 Dec 30;1(1):e000181. doi:10.1136/rmdopen2015-000181. eCollection 2015.; McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 Sep 19;386(9999):1137-46. doi:10.1016/S0140-6736(15)61134-5. Epub 2015 Jun 28.; Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4–CD8entheseal resident T cells. Nat Med. 2012 Jul 1; 18(7):1069-76. doi:10.1038/nm.2817.; McGonagle D, McInnes I, Kirkham B, et al. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum Dis. 2019 Sep;78(9):1167-78. doi:10.1136/annrheumdis-2019-215356. Epub 2019 Jul 5.; Calip GS, Patel PR, Adimadhyam S, et al. Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions. Int J Cancer. 2018 Sep 1;143(5):1062-71. doi:10.1002/ijc.31407. Epub 2018 Apr 16.; Li X, Andersen KM, Chang HY, et al. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. Ann Rheum Dis. 2020 Feb; 79(2):285-91. doi:10.1136/annrheumdis2019-216102. Epub 2019 Oct 31.; Lilly E. Taltz product monograph. Toronto; 2018.; Liu L, Lu J, Allan BW, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016 Apr 19;9:39-50. doi:10.2147/JIR.S100940.eCollection 2016.; Mease PJ, Smolen JS, Behrens F, et al. SPIRIT H2H study group. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded assessor trial. Ann Rheum Dis. 2020 Jan;79(1):123-31. doi:10.1136/annrheumdis2019-215386. Epub 2019 Sep 28.; Gower-Rousseau C, Salomez JL, Dupas JL, et al. Incidence of inflammatory bowel disease in northern France (19881990). Gut. 1994 Oct;35(10):1433-8. doi:10.1136/gut.35.10.1433.; Smolen JS, Schols M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international Task force. Ann Rheum Dis. 2018 Jan;77(1):3-17. doi:10.1136/annrheumdis-2017-211734. Epub 2017 Jul 6.; Busquets-Perez N, Rodriguez-Moreno J, Gуmez-Vaquero C, et al. Relationship between psoriatic arthritis and moderatesevere psoriasis: analysis of a series of 166 psoriatic arthritis patients selected from a hospital population. Clin Rheumatol. 2012 Jan;31(1):139-43. doi:10.1007/s10067-0111787-1. Epub 2011 Jun 24.; Feldman SR, Zhao Y, Shi L, et al. Economic and comorbidity burden among moderateto-severe psoriasis patients with comorbid psoriatic arthritis. Arthritis Care Res (Hoboken). 2015 May;67(5):708-17. doi:10.1002/acr.22492.; Muller B, Stekhoven D, Villiger P. Major differences in the pattern of joint swelling and tenderness in a large psoriatic arthritis cohort – results from an exploratory hierarchical cluster analysis. Arthritis Rheum. 2013;65:S141.; Tillett W, Lin CY, Trevelin Sprabery A, et al. Clinically Meaningful Improvement in Work Productivity Loss in Active Psoriatic Arthritis: Post-Hoc Analysis of SPIRIT-P1 and SPIRIT-P2 Trials. Clin Exp Rheumatol. 2020 May 11. Online ahead of print.; Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005 Oct;52(10):3279-89. doi:10.1002/art.21306.; Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017 Jan;76(1):79-87. doi:10.1136/annrheumdis-2016-209709. Epub 2016 Aug 23.; Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, doubleblind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017 Jun 10;389(10086):2317-27. doi:10.1016/S01406736(17)31429-0. Epub 2017 May 24.; Smolen JS, Mease P, Tahir H, et al. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naive to biological disease-modifying antirheumatic drug: final results by week 52. Ann Rheum Dis. 2020 Jul 13;annrheumdis-2020-217372. doi:10.1136/annrheumdis-2020-217372. Online ahead of print.

Διαθεσιμότητα: https://mrj.ima-press.net/mrj/article/view/1046
https://doi.org/10.14412/1996-7012-2020-3-50-56

The most frequent symptoms of joints damage among the residents of Yakutia

Συγγραφείς: S.S. Shadrina, R.N. Zakharova, A.A. Donskaya, A.N. Sergeeva

Πηγή: Yakut Medical Journal. :108-110

Θεματικοί όροι: 0301 basic medicine, 2. Zero hunger, radiological signs, 03 medical and health sciences, 0302 clinical medicine, поражение суставов, рентгенологические признаки, 15. Life on land, 10. No inequality, joint lesion, клинические симптомы, 3. Good health, clinical symptoms

The rs7574865 polymorphism of the STAT4 gene and risk of early rheumatoid arthritis development (the REMARKA study) ; Полиморфизм rs7574865 гена STAT4 и риск развития раннего ревматоидного артрита (исследование РЕМАРКА)

Συγγραφείς: I. A. Guseva, M. Yu. Krylov, N. V. Demidova, A. S. Avdeeva, A. V. Smirnov, E. Yu. Samarkina, E. L. Luchina, D. E. Karateev, E. L. Nasonov, И. А. Гусева, М. Ю. Крылов, Н. В. Демидова, А. С. Авдеева, А. В. Смирнов, Е. Ю. Самаркина, Е. Л. Лучихина, Д. Е. Каратеев, Е. Л. Насонов

Πηγή: Rheumatology Science and Practice; Vol 57, No 1 (2019); 62-65 ; Научно-практическая ревматология; Vol 57, No 1 (2019); 62-65 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: антитела к циклическим цитруллинированным пептидам, STAT4 gene, single nucleotide polymorphism, destructive joint damage, antibodies to cyclic citrullinated peptides, ген STAT4, однонуклеотидный полиморфизм, деструктивное поражение суставов

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2675/1802; Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Насонов ЕЛ, Насонова ВА, редакторы. Ревматология. Национальное руководство. Москва: ГЭОТАР-Медиа; 2008. С. 290-331 [Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: Nasonov EL, Nasonova VA, editors. Revmatologiya. Natsional'noe rukovodstvo [Rheumatology. National guidelance]. Moscow: GEOTARMedia; 2008. P. 290-331 (In Russ.)].; Wellcome Trust Case-Control Consortium. Genome-wide association study of 14000 cases of seven common diseases and 3000 shared controls. Nature. 2007;447:661-78.; Amos CI, Chen WV, Lee A, et al. High-density SNP analysis of 642 Caucasian families with rheumatoid arthritis identifies two new linkage regions on 11p12 and 2q33. Genes Immun. 2006;7(4):277-86. doi:10.1038/sj.gene.6364295; Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. New Engl J Med. 2007;357(10):977-86. doi:10.1056/NEJMoa073003; Elshazli R, Settin A. Association of PTPN22 rs2476601 and STAT4 rs7574865 polymorphisms with rheumatoid arthritis: A meta-analysis update. Immunobiology. 2015 220(8):1012-24. doi:10.1016/j.imbio.2015.04.003; Гусева ИА, Демидова НВ, Сорока НЕ и др. Молекулярно-генетическая характеристика раннего ревматоидного артрита. Молекулярная медицина. 2016;14(1):15-21 [Guseva IA, Demidova NV, Soroka NE, et al. Molecular genetic characteristics of early rheumatoid arthritis. Molekulyarnaya Meditsina. 2016;14(1):15-21 (In Russ.)].; Гусева ИА, Демидова НВ, Сорока НЕ и др. Исследование полиморфизмов генов-кандидатов иммунного ответа как маркеров риска развития ревматоидного артрита и продукции аутоантител. Научно-практическая ревматология. 2016;54(1):21-30 [Guseva IA, Demidova NV, Soroka NE, et al. Investigation of candidate gene polymorphisms in an immune response as markers for the risk of developing rheumatoid arthritis and producing autoantibodies. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(1):21-30 (In Russ.)]. doi:10.14412/1995-4484-2016-21-30; Насонов ЕЛ. Новые подходы к фармакотерапии ревматоидного артрита: тофацитиниб. Научно-практическая ревматология. 2014;52(2):209-21 [Nasonov EL. New approaches to pharmacotherapy of rheumatoid arthritis: tofacitinib. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(2):209-21 (In Russ.)]. doi:10.14412/1995-4484-2014-209-221; Korman BD, Kastner DL, Gregersen PK, Remmers EF. STAT4: genetics, mechanisms, and implications for autoimmunity. Curr Allergy Asthma Rep. 2008;8(5):398-403. doi:10.1007/s11882-008-0077-8; Horvath CM. STAT proteins and transcriptional responses to extracellular signals. Trends Biochem Sci. 2000;25(10):496-502. doi:10.1016/S0968-0004(00)01624-8; Lamana A, Lopez-Santalla M, Castillo-GonzЗlez R, et al. The Minor Allele of rs7574865 in the STAT4 Gene Is Associated with Increased mRNA and Protein Expression. PLoS One. 2015 Nov 16;10(11):e0142683. doi:10.1371/journal.pone.0142683; Frucht DM, Aringer M, Galon J. STAT4 is expressed in activated peripheral blood monocytes, dendritic cells, and macrophages at sites of Th1-mediated inflammation. J Immunol. 2000;164:4659-64. doi:10.4049/jimmunol.164.9.4659; Watford WT, Hissong BD, Bream JH, et al. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev. 2004;202:139-56. doi:10.1111/j.0105-2896.2004.00211.x; Tong G, Zhang X, Tong W, Liy Y. Association between polymorphism in STAT4 gene and risk of rheumatoid arthritis: meta-analysis. Hum Immunol. 2013; 74(5):586-92. doi:10.1016/j.humimm.2012.11.033; Ben Hamad M, Cornelis F, Mbarek H, et al. Signal transducer and activator of transcription and the risk of rheumatoid arthritis and thyroid autoimmune disorders. Clin Exp Rheumatol. 2011;29(2):269-74.; Lamana A, Balsa A, Rueda B, et al. The TT genotype of the STAT4 rs7574865 polymorphism is associated with high disease activity and disability in patients with early arthritis. PLoS One. 2012;7(8):e43661. doi:10.1371/journal.pone.0043661

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2675
https://doi.org/10.14412/1995-4484-2019-62-65

JOINT DAMAGE AFTER FROSTBITE (A CASE REPORT) ; Поражение суставов после отморожения (описание случая)

Συγγραφείς: Sh. F. Erdes, S. O. Krasnenko, M. M. Urumova, Ш. Ф. Эрдес, С. О. Красненко, М. М. Урумова

Πηγή: Rheumatology Science and Practice; Vol 56, No 4 (2018); 515-518 ; Научно-практическая ревматология; Vol 56, No 4 (2018); 515-518 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20184

Θεματικοί όροι: поражение суставов после отморожения, joint damage after frostbite

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2599/1742; Столяров ЕА, Грачев ВД. Термическая травма: Учебное пособие. Самара: СГМУ; 1995. 72 с.; Андреев ОВ, Самойленко ГЕ, Синяченко ОВ, Егудина ЕД. Эффективность лечения пострадавших от холодовой травмы. Травма. 2016;16(1):88-92; Гамзатова ПК, Однокозова ЮС. Клиническая характеристика отдаленного периода холодовой травмы. Бюллетень медицинских интернет-конференций. 2014;4(3):143; Шапкин ЮГ, Стекольников НЮ, Гамзатова ПК, Однокозова ЮС. Эндотелиальная дисфункция в отдаленном периоде холодовой травмы. Вестник экспериментальной; и клинической хирургии. 2014;7(4):359-63; Шапкин ЮГ, Стекольников НЮ, Гамзатова ПК, Мамедова ММК. Возможности коррекции эндотелиальной дисфункции при глубоких отморожениях конечностей. Современная наука: актуальные проблемы теории и практики (Серия: Естественные и технические науки). 2017;(9):106-9; Шаповалов КГ. Роль дисфункции эндотелия в альтерации тканей при местной холодовой травме. Тромбоз, гемостаз и реология. 2016;68(4):26-30; Гамзатова ПК, Однокозова ЮС. Классификация отдаленных осложнений холодовой травмы. Бюллетень медицинских интернет-конференций. 2014;4(8):996; Tishler JM. The 'soft-tissue and bone changes in frostbite injuries. Radiology. 1972;102:511-3. doi:10.1148/102.3.511; Vinson HA, Schatzki R. Roentgenologic bone changes encountered in frostbite, Korea. 1950-51. Radiology. 1954;63:685-95. doi:10.1148/63.5.685; Glick R, Parhami N. Frostbite arthritis. J Rheumatol. 1979;6:456-60.; Carrera GF, Kozin F, McCarty DJ. Arthritis after frostbite injury in children. Arthritis Rheum. 1979;22:1082-87. doi:10.1002/art.1780221006; Robert JR, McKendry A. Frostbite arthritis. CMA J. 1981;125:1128-30.; Kahn JE, Lidove O, Laredo JD, Bletry О. Frostbite arthritis. Ann Rheum Dis. 2005;64:966-7. doi:10.1136/ard.2004.027961; Gralino BJ, Porter JM, Rosch J. Angiography in the diagnosis and therapy of frostbite. Radiology. 1976;119:301-5. doi:10.1148/119.2.301

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2599
https://doi.org/10.14412/1995-4484-2018-515-518

Лучевые методы диагностики в определении тяжести поражения суставов у пациентов с анкилозирующим спондилоартритом

Συγγραφείς: Раевский Павел Иосифович, Pavel I. Raevskii, Гайнисламова Лилия Радиковна, Liliia R. Gainislamova

Πηγή: Relevant lines of scientific research: development prospects; № 2; 42-44 ; Актуальные направления научных исследований: перспективы развития; № 2; 42-44

Θεματικοί όροι: Болезнь Бехтерева, анкилозирующий спондилоартрит, поражение суставов

Περιγραφή αρχείου: text/html

Relation: info:eu-repo/semantics/altIdentifier/isbn/978-5-9500562-3-9; https://interactive-plus.ru/e-articles/418/Action418-463198.pdf; 1. Насонов Е.Л. Проблемы остеопороза в ревматологии / Под ред. Е.Л. Насонова, И.А. Скрипниковой, В.А. Насоновой. – М., 1997, – 357 c.; 2. Bessant R. How should clinicians manage osteoporosis in ankylosing spondylitis? / R. Bessant, A. Keat // The Journal of Rheumatology. – 2002. – 29 (7). – P. 1511–1519.; 3. Maghraoui A. Osteoporosis and ankylosing spondylitis / A. Maghraoui // Joint Bone Spine. – 2004. – 7 (4). – P. 291–295.; 4. Mitra D. The prevalence of vertebral compression fractures in mild ankylosing spondylitis and their relationship to bone mineral density / D. Mitra, D.M. Elvins, D.J. Spenden [et al.] // Rheumatology (Oxford). – 2000. – №39. – P. 85–89.; 5. Reveille J.D. Spondyloarthritis; update on pathogenesis and management / J.D. Reveille, F.C. Arnett // The American Journal of Medicine. – 2005. – 118 (6). – P. 592–603.

Διαθεσιμότητα: https://interactive-plus.ru/files/Books/Cover-418.jpg?req=463198
https://interactive-plus.ru/article/463198/discussion_platform

Analysis of necessity in physical rehabilitation of ATO participants and tactics of reconstruc- tion of military servants with the damage of joins

Πηγή: Спортивна медицина і фізична реабілітація; № 1 (2018); 93-100
Sports medicine and physical rehabilitation; № 1 (2018); 93-100
Спортивная медицина и физическая реабилитация; № 1 (2018); 93-100

Θεματικοί όροι: физическая реабилитация, участники АТО, поражение суставов, фізична реабілітація, учасники АТО, ураження суглобів, physical rehabilitation, ATO participants, joint lesions, 3. Good health

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: http://sportmedicine.uni-sport.edu.ua/article/view/179963

ASSOCIATION OF BLOOD GENE EXPRESSIONS IN RHEUMATOID ARTHRITIS PATIENTS WITH CLINICAL AND LABORATORY PARAMETERS BEFORE AND AFTER METHOTREXATE THERAPY ; Ассоциация экспрессии генов в крови больных ревматоидным артритом с клиническими и лабораторными показателями до и после терапии метотрексатом

Συγγραφείς: E. V. Chetina, N. V. Demidova, D. E. Karateev, G. A. Markova, M. A. Makarov, V. V. Kolomatsky, A. L. Logunov, E. A. Naryshkin, M. M. Lipina, S. A. Makarov, A. N. Kuzin, Е. В. Четина, Н. В. Демидова, Д. Е. Каратеев, Г. А. Маркова, М. А. Макаров, В. В. Коломацкий, А. Л. Логунов, Е. А. Нарышкин, М. М. Липина, С. А. Макаров, А. Н. Кузин

Πηγή: Rheumatology Science and Practice; Vol 54, No 2 (2016); 155-163 ; Научно-практическая ревматология; Vol 54, No 2 (2016); 155-163 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20162

Θεματικοί όροι: метотрексат, gene expression, peripheral blood, inflammation, joint injury, methotrexate, экспрессия генов, периферическая кровь, воспаление, поражение суставов

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2210/1427; Насонов ЕЛ. Применение ритуксимаба при ревматоидном артрите. В кн.: Насонов ЕЛ, редактор. Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Москва: ИМА-ПРЕСС; 2012. С. 55-93 [Nasonov EL. The use of rituximab in rheumatoid arthritis. In: Nasonov EL, editor. Anti-B-kletochnaya terapiya v revmatologii: fokus na rituksimab [Anti-B-cell therapy in rheumatology: Focus on rituximab]. Moscow: IMAPRESS; 2012. P. 55-93].; Harris ED Jr. Rheumatoid Arthritis: pathophysiology and implications for therapy. N Engl J Med. 1990;322:1277-89. doi:10.1056/NEJM199005033221805; Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26-37. doi:10.1002/art.21519; Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial. Lancet. 2008;372(9636):375-82. doi:10.1016/S0140-6736(08)61000-4; De Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, et al. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum. 2008;58(5):1293-8. doi:10.1002/art.23439; Burmester GR, Mariette X, Montecucco C, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis. 2007;66(6):732-9. doi:10.1136/ard.2006.066761; Klareskog L, van der Heijde HD, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410):675-81. doi:10.1016/S0140-6736(04)15640-7; Emery P, Genovese MC, van VR, et al. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol. 2009;36(7):1429-41. doi:10.3899/jrheum.081018; Tchetina EV, Squires G, Poole AR. Increased type II collagen degradation and very early focal cartilage degeneration is associated with upregulation of chondrocyte differentiation related genes in early human articular cartilage lesions. J Rheumatol. 2005;32(5):876-86.; Burska AN, Roget K, Blits M, et al. Gene expression analysis in RA: towards personalized medicine. Pharmacogenomics J. 2014;14(2):93-106. doi:10.1038/tpj.2013.48; Blits M, Jansen G, Assaraf YG, et al. Methotrexate normalizes upregulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum. 2013;65(11):2791-802. doi:10.1002/art.38094; Tchetina ЕV, Demidova NV, Semyonova LA, et al. Differential expression of mammalian target of rapamycin (mTOR) in the peripheral blood of early-stage rheumatoid arthritis patients as a prognostic marker of the disease activity and knee joint destruction: a two year follow-up study. Ann Rheum Dis. 2010;69 Suppl 3:675.; Четина ЕВ, Демидова НВ, Каратеев ДЕ, Насонов ЕЛ. Гетерогенность первичных больных ревматоидным артритом по экспрессии генов в крови: теоретические основы дифференциального подхода к терапии. Научно-практическая ревматология. 2011;49(4):24-30 [Chetina EV, Demidova NV, Karateev DE, Nasovov EL. Heterogeneity of early rheumatoid arthritis patients according to blood gene expression: theoretical bases of a differential therapy approach. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2011;49(4):24-30 (In Russ.)]. doi:10.14412/1995-4484- 2011-57; Четина ЕВ, Семенова ЛА, Логунов АЛ и др. Повышенная экспрессия регуляторных генов в крови и суставном хряще больных ревматоидным артритом. Научно-практическая ревматология. 2012;50(4):44-8. [Chetina EV, Semyonova LA, Logunov AL, et al. Enhanced regulatory gene expressions in the blood and articular cartilage of patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(4):44-8 (In Russ.)]. doi:10.14412/1995- 4484-2012-1111; Четина ЕВ, Демидова НВ, Каратеев ДЕ, Насонов ЕЛ. Анализ экспрессии генов в крови как дополнительный инструмент мониторинга терапии метотрексатом больных ревматоидным артритом. Научно-практическая ревматология. 2013;51(6):654-61 [Chetina EV, Demidova NV, Karateev DE, Nasonov EL. Analysis of gene expression in blood as an additional tool to monitor methotrexate therapy in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(6):654-61(In Russ.)]. doi:10.14412/1995-4484-2013-654-61; Четина ЕВ, Пиванова АВ, Кузикянц КХ и др. Мониторинг терапии ритуксимабом больных ревматоидным артритом посредством анализа экспрессии генов в периферической крови. Научно-практическая ревматология. 2014;52(3):263-9 [Chetina EV, Pivanova AV, Kuzikyants KK, et al. Rituximab therapy monitoring in patients with rheumatoid arthritis hrough peripheral blood gene expression analysis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(3):263-9 (In Russ.)]. doi:10.14412/1995-4484- 2014-263-269; Tchetina EV, Demidova NV, Karateev DE, Nasonov EL. Rheumatoid factor positivity is associated with increased joint destruction and upregulation of matrix metalloproteinase 9 and cathepsin K gene expression in the peripheral blood in rheumatoid arthritis patients treated with methotrexate. Int J Rheumatol. 2013;2013:Article ID 457876. doi:10.1155/2013/457876; Hä upl T, Yahyawi M, Lü bke C, et al. Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007;12(3):328-40. doi:10.1177/1087057107299261; Walsh NC, Reinwald S, Manning CA, et al. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res. 2009;24(9):1572-85. doi:10.1359/jbmr.090320; Komori T. Regulation of bone development and maintenance by Runx2. Front Biosci. 2008;13:898-903. doi:10.2741/2730; Alliston T. TGF-β regulation of osteoblast differentiation and bone properties. J Musculoskelet Neuronal Interact. 2006;6(4):349-50.; Kim J, Jung Y, Sun H, et al. Erythropoietin mediated bone formation is regulated by mTOR signaling. J Cell Biochem. 2012;113(1):220-8. doi:10.1002/jcb.23347; Tang CH, Lu DY, Tan TW, et al. Ultrasound induces hypoxiainducible factor-1 activation and inducible nitric-oxide synthase expression through the integrin/integrin-linked kinase/Akt/mammalian target of rapamycin pathway in osteoblasts. J Biol Chem. 2007;282(35):25406-15. doi:10.1074/jbc.M701001200; Grcevic D, Jajic Z, Kovacic N, et al. Peripheral blood expression profiles of bone morphogenetic proteins, tumor necrosis factorsuperfamily molecules, and transcription factor Runx2 could be used as markers of the form of arthritis, disease activity, and therapeutic responsiveness. J Rheumatol. 2010;37(2):246-256. doi:10.3899/jrheum.090167; Pohlers D, Beyer A, Koczan D, et al. Constitutive upregulation of the transforming growth factor-beta pathway in rheumatoid arthritis synovial fibroblasts. Arthritis Res Ther. 2007;9(3):R59. doi:10.1186/ar2217; Rooney T, Roux-Lombard P, Veale DJ, et al. Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression: analysis of a proof-of-concept randomised clinical trial of cytokine blockade. Ann Rheum Dis. 2010;69(4):706-14. doi:10.1136/ard.2009.108324; Четина ЕВ, ДиБатиста Д, Пул АР. Роль простагландина E2 в ингибировании разрушения коллагена суставного хряща больных остеоартрозом. Научно-практическая ревматология. 2009;47(3):18-23 [Chetina EV, DiBattista D, Pool AR. Prostaglandin E2 role in inhibition of joint cartilage collagen destruction in patients with osteoarthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2009;47(3):18-24. (In Russ.)]. doi:10.14412/1995-4484- 2009-1308; Yoshimura N, Ohmoto Y, Yasui H, et al. The direct effect of FK506 and rapamycin on interleukin 1(beta) and immunoglobulin production in vitro. Transplantation. 1994;57(12):1815-8. doi:10.1097/00007890-199457120-00024; Foey AD, Feldmann M, Brennan FM. CD40 ligation induces macrophage IL-10 and TNF-alpha production: differential use of the PI3K and p42/44 MAPK-pathways. Cytokine. 2001;16(4):131- 42. doi:10.1006/cyto.2001.0954; Carlson RP, Hartman DA, Tomchek LA, et al. Rapamycin, a potential disease-modifying antiarthritic drug. J Pharmacol Exp Ther. 1993;266(2):1125-38.; Bruyn GA, Tate G, Caeiro F, et al. Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study. Ann Rheum Dis. 2008;67(8):1090-5. doi:10.1136/ard.2007.078808; Sugatani T, Hruska KA. Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J Biol Chem. 2005;280(5):3583-9. doi:10.1074/jbc.M410480200; Glantschnig H, Fisher JE, Wesolowski G, et al. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ. 2003;10(10):1165-77. doi:10.1038/sj.cdd.4401285; Cejka D, Hayer S, Niederreiter B, et al. Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis. Arthritis Rheum. 2010;62(8):2294-302. doi:10.1002/art.27504; Laragione T, Gulko PS. mTOR regulates the invasive properties of synovial fibroblasts in rheumatoid arthritis. Mol Med. 2010;16(9- 10):352-8. doi:10.2119/molmed.2010.00049; Kneissel M, Luong-Nguyen NH, Baptist M, et al. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. Bone. 2004;35(5):1144-56. doi:10.1016/j.bone.2004.07.013; Welsing PM, van Gestel AM, Swinkels HL, et al. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum. 2001;44(9):2009-17. doi:10.1002/1529- 0131(200109)44:93.0.CO;2-L; Xue M, McKelvey K, Shen K, et al. Endogenous MMP-9 and not MMP-2 promotes rheumatoid synovial fibroblast survival, inflammation and cartilage degradation. Rheumatology (Oxford). 2014 Jun 29. pii: keu254. [Epub ahead of print].; Grassi F, Cristino S, Toneguzzi S, et al. CXCL12 chemokine upregulates bone resorption and MMP-9 release by human osteoclasts: CXCL12 levels are increased in synovial and bone tissue of rheumatoid arthritis patients. J Cell Physiol. 2004;199(2):244-51. doi.org/10.1002/jcp.10445; Kaneko M, Tomita T, Nakase T, et al. Expression of proteinases and inflammatory cytokines in subchondral bone regions in the destructive joint of rheumatoid arthritis. Rheumatology (Oxford). 2001;40(3):247-55. doi:10.1093/rheumatology/40.3.247; Kim KS, Choi HM, Lee YA, et al. Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis. Rheumatol Int. 2011;31(4):543-7. doi:10.1007/s00296-010- 1592-1; Chia WT, Chen YW, Cheng LY, et al. MMP-9 mRNA as a therapeutic marker in acute and chronic stages of arthritis induced by type II collagen antibody. J Formos Med Assoc. 2008;107(3):245- 52. doi:10.1016/S0929-6646(08)60143-6; Senolt L, Grigorian M, Lukanidin E, et al. S100A4 is expressed at site of invasion in rheumatoid arthritis synovium and modulates production of matrix metalloproteinases. Ann Rheum Dis. 2006;65(12):1645-8. doi:10.1136/ard.2005.047704; Di Girolamo N, Indoh I, Jackson N, et al. Human mast cellderived gelatinase B (matrix metalloproteinase-9) is regulated by inflammatory cytokines: role in cell migration. J Immunol. 2006;177(4):2638-50. doi:10.4049/jimmunol.177.4.2638; Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci. 2006;11:529-43. doi:10.2741/1817; Richardson VJ. Divergent and synergistic regulation of matrix metalloprotease production by cytokines in combination with C-C chemokines. Int J Immunopathol Pharmacol. 2010;23(3):715-26.; Huang JL, Wu SY, Xie XJ, et al. Inhibiting effects of Leflunomide metabolite on overexpression of CD147, MMP-2 and MMP-9 in PMA differentiated THP-1 cells. Eur J Pharmacol. 2011;670(1):304-10. doi:10.1016/j.ejphar.2011.07.045; Vandooren B, Kruithof E, Yu DT, et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum. 2004;50(9):2942-53. doi:10.1002/art.20477; Matsushita I, Uzuki M, Matsuno H, et al. Rheumatoid nodulosis during methotrexate therapy in a patient with rheumatoid arthritis. Mod Rheumatol. 2006;16(6):401-3. doi:10.3109/s10165-006- 0522-2; Van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, et al. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients. Ann Rheum Dis. 2008;67(4):563-6. doi:10.1136/ard.2007.081950; Lindberg J, af Klint E, Catrina AI, et al. Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients. Arthritis Res Ther. 2006;8(6):R179. doi:10.1186/ar2090; Catrina AI, Ulfgren AK, Lindblad S, et al. Low levels of apoptosis and high FLIP expression in early rheumatoid arthritis synovium. Ann Rheum Dis. 2002;61(10):934-6. doi:10.1136/ard.61.10.934; Rasa K, Scheel-Toellner D, Lee C-Y, et al. Synovial fluid apoptosis is inhibited in patients with very early rheumatoid arthritis. Arthritis Res Ther. 2006;8(4):R120. doi:10.1186/ar2009; Eguchi K. Apoptosis in autoimmune diseases. Intern Med. 2001;40(4):275-84. doi:10.2169/internalmedicine.40.275; Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun. 2010;11:180-210. doi:10.1159/000289205; Eddy LJ, Goeddel DV, Wong GH. Tumor necrosis factor-alpha pretreatment is protective in a rat model of myocardial ischemiareperfusion injury. Biochem Biophys Res Commun. 1992;184(2):1056-9. doi:10.1016/0006-291X(92)90698-K; Nelson SK, Wong GH, McCord JM. Leukemia inhibitory factor and tumor necrosis factor induce manganese superoxide dismutase and protect rabbit hearts from reperfusion injury. J Mol Cell Cardiol. 1995;27(1):223-9. doi:10.1016/S0022-2828(08)80021-1; Yamashita N, Hoshida S, Otsu K, et al. The involvement of cytokines in the second window of ischaemic preconditioning. Br J Pharmacol. 2000;131(3):415-22. doi:10.1038/sj.bjp.0703594; Lecour S, James RW. When are pro-inflammatory cytokines safe in heart failure? Eur Heart J. 2011;32(6):680-5. doi:10.1093/eurheartj/ehq484; Burchfield JS, Dong JW, Sakata Y, et al. The cytoprotective effects of tumor necrosis factor are conveyed through tumor necrosis factor receptor-associated factor 2 in the heart. Circ Heart Fail. 2010;3(1):157-64. doi:10.1161/CIRCHEARTFAILURE.109.899732

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2210
https://doi.org/10.14412/1995-4484-2016-155-163

JOINT INVOLVEMENT IN SYPHILIS ; ПОРАЖЕНИЕ СУСТАВОВ ПРИ СИФИЛИСЕ

Συγγραφείς: T. I. Zlobina, A. A. Melnikova, A. N. Kalyagin, Т. И. Злобина, А. А. Мельникова, А. Н. Калягин

Πηγή: Modern Rheumatology Journal; Том 10, № 4 (2016); 69-72 ; Современная ревматология; Том 10, № 4 (2016); 69-72 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2016-4

Θεματικοί όροι: сифилис костей и суставов, joint involvement in syphilis, osteoarthritis, joint destruction, gumma, osteosclerosis, syphilis of bones and joints, поражение суставов при сифилисе, остеоартрит, деструкция сустава, гумма, остеосклероз

Περιγραφή αρχείου: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/722/701; Сафьянникова АА, Ботвинкин АД, Якубович АИ и др. Сравнительный эпидемиологический анализ заболеваемости сифилисом и гонококковой инфекцией в Иркутской области. Сибирский медицинский журнал (Иркутск). 2009;91(8):85-7. [Saf'yannikova AA, Botvinkin AD, Yakubovich AI, et al. Comparative epidemiologic analysis of syphilis and gonococcal infection morbidity in Irkutsk region. Sibirskii meditsinskii zhurnal (Irkutsk). 2009;91(8): 85-7. (In Russ.)].; Кубанова АА, Кубанов АА, Мелехина ЛЕ, Богданова ЕВ. Заболеваемость сифилисом в Российской Федерации в 2010-2014 гг. Вестник дерматологии и венерологии. 2015;(5):15-23. [Kubanova AA, Kubanov AA, Melekhina LE, Bogdanova EV. Syphilis incidence rate in the Russian Federation in 20102014. Vestnik dermatologii i venerologii. 2015;(5):15-23. (In Russ.)].; Прохоренков ВИ, Родиков МВ, Шпрах ВВ. Профессор С.П. Боткин о сифилитическом поражении печени. Сибирский медицинский журнал (Иркутск). 2010;97(6):262-5. [Prokhorenkov VI, Rodikov MV, Shprakh VV. Professor S.P. Botkin about syphilitic injury of liver. Sibirskii meditsinskii zhurnal (Irkutsk). 2010; 97(6):262-5. (In Russ.)].; Родиков МВ, Шпрах ВВ. Состояние цереброспинальной жидкости у больных с ранним и поздним нейросифилисом. Сибирский медицинский журнал (Иркутск). 2009;88(5):15-7. [Rodikov MV, Shprakh VV. State of cerebrospinal fluid in patients with early and late neurosyphilis. Sibirskii meditsinskii zhurnal (Irkutsk). 2009;88(5): 15-7. (In Russ.)].; Родиков МВ, Шпрах ВВ. Наблюдение летальных случаев при нейросифилисе. Сибирский медицинский журнал (Иркутск). 2010;97(6):255-7. [Rodikov MV, Shprakh VV. Observation of lethal cases in neurosyphilis. Sibirskii meditsinskii zhurnal (Irkutsk). 2010; 97(6): 255-257. (In Russ.)].; Бархатов МВ, Родиков МВ, Шпрах ВВ. Специфическая терапия поздних форм нейросифилиса в условиях «прорыва» гематоэнцефалического барьера. Сибирский медицинский журнал (Иркутск). 2010;97(6):138-41. [Barkhatov MV, Rodikov MV, Shprakh VV. Spetsificheskaya terapiya pozdnikh form neirosifilisa v usloviyakh «proryva» gematoentsefalicheskogo bar'era. Sibirskii meditsinskii zhurnal (Irkutsk). 2010;97(6):138-41. (In Russ.)].; Мавлютова ГИ, Юсупова ЛА, Мисбахова АГ. Поздние формы сифилиса: современное состояние проблемы. Лечащий врач. 2015;(6):73-7. [Mavlyutova GI, Yusupova LA, Misbakhova AG. Late forms of syphilis: modern state of the issue. Lechashchii vrach. 2015;(6):73-7. (In Russ.)].; Кубанов АА, Катунин ГЛ, Китаева НВ и др. Специфическое поражение коленного сустава у больного сифилисом. Вестник дерматологии и венерологии. 2010;(5):103-7. [Kubanov AA, Katunin GL, Kitaeva NV, et al. Specific lesion of the knee joint in a patient with syphilis. Vestnik dermatologii i venerologii. 2010;(5):103-7. (In Russ.)].; Turner P. Syphilitic Cirrhosis of the Liver; Ascites; Talma-Morison Operation; Arthritis of the Knee. Proc R Soc Med. 1914;7 (Sect Study Dis Child):124-6.; Левинская ДИ. Поражение костей и суставов при вторичном сифилисе. Здравоохранение Дальнего Востока. 2010;(1): 61-2. [Levinskaya DI. Bones and joints disorders at a secondary syphilis. Zdravookhranenie Dal'nego Vostoka. 2010;(1):61-2. (In Russ.)].; Осипок НВ, Горяев ЮА, Калягин АН. Инфекционные артриты. Журнал инфекционной патологии. 2005;12(3-4):11-20. [Osipok NV, Goryaev YuA, Kalyagin AN. Infectious arthritises. Zhurnal infektsionnoi patologii. 2005;12(3-4):11-20. (In Russ.)].; Bernard S, Epaulard O, Baillet A, et al. Syphilitic arthropathy: a case report with positive PCR. Presse Med. 2012 Mar;41 (3 Pt 1):320-3. doi:10.1016/j.lpm.2011.08.005. Epub 2011 Oct 4.

Διαθεσιμότητα: https://mrj.ima-press.net/mrj/article/view/722
https://doi.org/10.14412/1996-7012-2016-4-69-72

Узловатая эритема при синдроме Лефгрена

Συγγραφείς: КАРПОВА Ю.А., БЕЛОВ Б.С., ЕГОРОВА О.Н., САВУШКИНА Н.М., ГЛУХОВА С.И., РАДЕНСКА-ЛОПОВОК С.Г.

Θεματικοί όροι: САРКОИДОЗ,СИНДРОМ ЛЕФГРЕНА,УЗЛОВАТАЯ ЭРИТЕМА,ПОРАЖЕНИЕ СУСТАВОВ,ГРАНУЛЕМАТОЗНОЕ ВОСПАЛЕНИЕ,ПАННИКУЛИТ,КОМПЬЮТЕРНАЯ ТОМОГРАФИЯ,ВНУТРИГРУДНАЯ ЛИМФАДЕНОПАТИЯ,ФЕНОМЕН "МАТОВОГО СТЕКЛА",ДИАГНОСТИКА,ФАРМАКОТЕРАПИЯ

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/uzlovataya-eritema-pri-sindrome-lefgrena
http://cyberleninka.ru/article_covers/16869979.png

ANALYSIS OF GENE EXPRESSION IN BLOOD AS AN ADDITIONAL TOOL TO MONITOR METHOTREXATE THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS ; Анализ экспрессии генов в крови как дополнительный инструмент мониторинга терапии метотрексатом больных ревматоидным артритом

Συγγραφείς: Elena Vasilyevna Chetina, N V Demidova, D E Karateev, E L Nasonov, Н. В. Демидова, Дмитрий Евгеньевич Каратеев, Евгений Львович Насонов

Πηγή: Rheumatology Science and Practice; Vol 51, No 6 (2013); 654-61 ; Научно-практическая ревматология; Vol 51, No 6 (2013); 654-61 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2013-6

Θεματικοί όροι: метотрексат, gene expression, peripheral blood, inflammation, joint lesion, methotrexate, экспрессия генов, периферическая кровь, воспаление, поражение суставов

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/1348/1008; Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. Ревматология. Национальное руководство. Насонов ЕЛ, Насонова ВА, редакторы. Москва: ГЭОТАР-Медиа; 2008: С. 290–331. [Nasonov EL, Karateev DE, Balabanova RM. Revmatoidnyi artrit. Revmatologiya. Natsional'noe rukovodstvo. Nasonov EL, Nasonova VA, redaktory. Moskva: GEOTAR-Media; 2008: S. 290–331.] Harris ED Jr. Rheumatoid Arthritis: pathophysiology and implications for therapy. N Engl J Med. 1990;322(18):1277–89. DOI: http://dx.doi.org/10.1056/NEJM199005033221805. Firenstein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423(6937):356–61. DOI: http://dx.doi.org/10.1038/nature01661. Rindfleisch JA, Muller D. Diagnosis and management of rheumatoid arthritis. Am Fam Physician. 2005;72(6):1037–47. Visser H, le Cessie S, Vos K, et al. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum. 2002;46(2):357–65. DOI: http://dx.doi.org/10.1002/art.10117. Machold KP, Stamm TA, Nell VP, et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford). 2007;46(2):342–9. DOI: http://dx.doi.org/10.1093/rheumatology/kel237. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum. 2004;50(3):709–15. DOI: http://dx.doi.org/10.1002/art.20044. Polzer K, Baeten D, Soleiman A, et al. Tumour necrosis factor blockade increases lymphangiogenesis in murine and human arthritic joints. Ann Rheum Dis. 2008;67(11):1610–6. DOI:10.1136/ard.2007.083394. Tchetina EV, Squires G, Poole AR. Increased type II collagen degradation and very early focal cartilage degeneration is associated with upregulation of chondrocyte differentiation related genes in early human articular cartilage lesions. J Rheumatol. 2005;32(5):876–86. Karouzakis E, Neidhart M, Gay RE, Gay S. Molecular and cellular basis of rheumatoid joint destruction. Immunology Letters. 2006;106(1):8–13. DOI: http://dx.doi.org/10.1016/j.imlet.2006.04.011. Grcevic D, Jajic Z, Kovacic N, et al. Peripheral blood expression profiles of bone morphogenetic proteins, tumor necrosis factor-superfamily molecules, and transcription factor Runx2 could be used as markers of the form of arthritis, disease activity, and therapeutic responsiveness. J Rheumatol. 2010;37(2):246–56. DOI:10.3899/jrheum.090167. Olsen N, Sokka T, Seehorn CL, et al. A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells. Ann Rheum Dis. 2004;63(11):1387–92. DOI: http://dx.doi.org/10.1136/ard.2003.017194. Van der Pouw Kraan TC, Wijbrandts CA, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis. 2007;66(8):1008–14. DOI: http://dx.doi.org/10.1136/ard.2006.063412. Haas CS, Creighton CJ, Pi X, et al. Identification of genes modulated in rheumatoid arthritis using complementary DNA microarray analysis of lymphoblastoid B cell lines from disease-discordant monozygotic twins. Arthritis Rheum. 2006;54(7):2047–60. DOI: http://dx.doi.org/10.1002/art.21953. Tchetina ЕV, Demidova NV, Semyonova LA, et al. Differential expression of mammalian target of rapamycin (mTOR) in the peripheral blood of early-stage rheumatoid arthritis patients as a prognostic marker of the disease activity and knee joint destruction: a two year follow-up study. Ann Rheum Dis. 2010;69 Suppl 3:675. Четина ЕВ, Демидова НВ, Каратеев ДЕ, Насонов ЕЛ. Гетерогенность первичных больных ревматоидным артритом по экспрессии генов в крови: теоретические основы дифференциального подхода к терапии. Научно-практическая ревматология. 2011;(4):24–30. [Chetina EV, Demidova NV, Karateev DE, Nasovov EL. Heterogeneity of early rheumatoid arthritis patients according to blood gene expression: theoretical bases of a differential therapy approach. Rheumatology Science and Practice. 2011;(4):24–30.]. DOI: http://dx.doi.org/10.14412/1995-4484-2011-57. Четина ЕВ, Семенова ЛА, Логунов АЛ и др. Повышенная экспрессия регуляторных генов в крови и суставном хряще больных ревматоидным артритом. Научно-практическая ревматология. 2012;(4):44–8. [Chetina EV, Semyonova LA, Logunov AL, et al. Enhanced regulatory gene expressions in the blood and articular cartilage of patients with rheumatoid arthritis. Rheumatology Science and Practice. 2012;(4):44–8.]. DOI: http://dx.doi.org/10.14412/1995-4484-2012-1111. Hay N, Sonnenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18(16):1926–45. DOI: http://dx.doi.org/10.1101/gad.1212704. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 1991;253(5022):905–9. DOI: http://dx.doi.org/10.1126/science.1715094. Yoshimura N, Ohmoto Y, Yasui H, et al. The direct effect of FK506 and rapamycin on interleukin 1(beta) and immunoglobulin production in vitro. Transplantation. 1994;57(12):1815–8. Foey AD, Feldmann M, Brennan FM. CD40 ligation induces macrophage IL-10 and TNF-alpha production: differential use of the PI3K and p42/44 MAPK-pathways. Cytokine. 2001;16(4):131–42. DOI: http://dx.doi.org/10.1006/cyto.2001.0954. Carlson RP, Hartman DA, Tomchek LA, et al. Rapamycin, a potential disease-modifying antiarthritic drug. J Pharmacol Exp Ther. 1993;266(2):1125–38. Lum JJ, DeBerardinis RJ, Thompson CB. Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol. 2005;6(6):439–48. DOI: http://dx.doi.org/10.1038/nrm1660. Lleo A, Invernizzi P, Selmi C, et al. Autophagy: highlighning a novel player in the autoimmunity scenario. J Autoimmun. 2007;29(2–3):61–8. DOI: http://dx.doi.org/10.1016/j.jaut.2007.06.003. Lu B, Capan E, Li C. Autophagy induction and autophagic cell death in effector T cells. Autophagy. 2007;3(2):158–9. Boya P, Gonzalez-Polo RA, Casares N, et al. Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol. 2005;25(3):1025–40. DOI: http://dx.doi.org/10.1128/MCB.25.3.1025-1040.2005. Shin YJ, Han SH, Kim DS, et al. Autophagy induction and CHOP under-expression promotes survival of fibroblasts from rheumatoid arthritis patients under endoplasmic reticulum stress. Arthritis Res Ther. 2010;12(1):R19. DOI:10.1186/ar2921. Catrina AI, Ulfgren AK, Lindblad S, et al. Low levels of apoptosis and high FLIP expression in early rheumatoid arthritis synovium. Ann Rheum Dis. 2002;61(10):934–6. DOI: http://dx.doi.org/10.1136/ard.61.10.934. Rasa K, Scheel-Toellner D, Lee C-Y, et al. Synovial fluid apoptosis is inhibited in patients with very early rheumatoid arthritis. Arthritis Res Ther. 2006;8(4):R120. DOI: http://dx.doi.org/10.1186/ar2009. Eguchi K. Apoptosis in autoimmune diseases. Intern Med. 2001;40(4):275–84. DOI: http://dx.doi.org/10.2169/internalmedicine.40.275. Welsing PM, van Gestel AM, Swinkels HL, et al. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum. 2001;44(9):2009–17. DOI: http://dx.doi.org/10.1002/1529-0131(200109)44:9%3C2009::AID-ART349%3E3.0.CO;2-L. Grassi F, Cristino S, Toneguzzi S, et al. CXCL12 chemokine up-regulates bone resorption and MMP-9 release by human osteoclasts: CXCL12 levels are increased in synovial and bone tissue of rheumatoid arthritis patients. J Cell Physiol. 2004;199(2):244–51. DOI: http://dx.doi.org/10.1002/jcp.10445. Kaneko M, Tomita T, Nakase T, et al. Expression of proteinases and inflammatory cytokines in subchondral bone regions in the destructive joint of rheumatoid arthritis. Rheumatology (Oxford). 2001;40(3):247–55. DOI: http://dx.doi.org/10.1093/rheumatology/40.3.247. Kim KS, Choi HM, Lee YA, et al. Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis. Rheumatol Int. 2011;31(4):543-7. DOI:10.1007/s00296-010-1592-1. Chia WT, Chen YW, Cheng LY, et al. MMP-9 mRNA as a therapeutic marker in acute and chronic stages of arthritis induced by type II collagen antibody. J Formos Med Assoc. 2008;107(3):245–52. DOI: http://dx.doi.org/10.1016/S0929-6646(08)60143-6. Senolt L, Grigorian M, Lukanidin E, et al. S100A4 is expressed at site of invasion in rheumatoid arthritis synovium and modulates production of matrix metalloproteinases. Ann Rheum Dis. 2006;65(12):1645–8. DOI: http://dx.doi.org/10.1136/ard.2005.047704. Di Girolamo N, Indoh I, Jackson N, et al. Human mast cell-derived gelatinase B (matrix metalloproteinase-9) is regulated by inflammatory cytokines: role in cell migration. J Immunol. 2006;177(4):2638–50. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci. 2006;11:529–43. DOI: http://dx.doi.org/10.2741/1817. Richardson VJ. Divergent and synergistic regulation of matrix metalloprotease production by cytokines in combination with C-C chemokines. Int J Immunopathol Pharmacol. 2010;23(3):715–26. Huang JL, Wu SY, Xie XJ, et al. Inhibiting effects of Leflunomide metabolite on overexpression of CD147, MMP-2 and MMP-9 in PMA differentiated THP-1 cells. Eur J Pharmacol. 2011;670(1):304–10. DOI:10.1016/j.ejphar.2011.07.045. Vandooren B, Kruithof E, Yu DT, et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum. 2004;50(9):2942–53. DOI: http://dx.doi.org/10.1002/art.20477. Matsushita I, Uzuki M, Matsuno H, et al. Rheumatoid nodulosis during methotrexate therapy in a patient with rheumatoid arthritis. Mod Rheumatol. 2006;16(6):401–3. DOI: http://dx.doi.org/10.1007/s10165-006-0522-2. Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44–8. DOI: http://dx.doi.org/10.1002/art.1780380107. Prevoo ML, van Gestel AM, van T Hof MA, et al. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol. 1996;35(11):1101–5. DOI: http://dx.doi.org/10.1093/rheumatology/35.11.1101. Van der Heijde DM. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 1999;26(3):743–5. Van der Heijde DM, Dankert T, et al. Reliability and sensitivity to change of a simplification of the Sharp/van der Heijde radiological assessment in rheumatoid arthritis. Rheumatology (Oxford). 1999;38(10):941–7. DOI: http://dx.doi.org/10.1093/rheumatology/38.10.941. Четина ЕВ, ДиБатиста Д, Пул АР. Роль простагландина E2 в ингибировании разрушения коллагена суставного хряща больных остеоартрозом. Научно-практическая ревматология. 2009;(3):18–24. [Chetina EV, DiBattista D, Pool AR. Prostaglandin E2 role in inhibition of joint cartilage collagen destruction in patients with osteoarthritis. Rheumatology Science and Practice. 2009;(3):18–24.]. DOI: http://dx.doi.org/10.14412/1995-4484-2009-1308. Weinblatt ME, Kaplan H, Germain BF, et al. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum. 1994;37(10):1492–8. DOI: http://dx.doi.org/10.1002/art.1780371013. Machold KP, Stamm TA, Nell VP, et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford). 2007;46(2):342–9. DOI: http://dx.doi.org/10.1093/rheumatology/kel237. Schett G, Stach C, Zwerina J, et al. How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum. 2008;58(10):2936–48. DOI:10.1002/art.23951. Gossec L, Dougados M, Goupille P, et al. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis. 2004;63(6):675–80. DOI: http://dx.doi.org/10.1136/ard.2003.010611. Mottonen T, Paimela L, Leirisalo-Repo M, et al. Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with "sawtooth" strategy. Ann Rheum Dis. 1998;57(9):533–9. DOI: http://dx.doi.org/10.1136/ard.57.9.533. Eberhardt K, Fex E. Clinical course and remission rate in patients with early rheumatoid arthritis: relationship to outcome after 5 years. Br J Rheumatol. 1998;37(12):1324–9. DOI: http://dx.doi.org/10.1093/rheumatology/37.12.1324. Forslind K, Hafstrom I, Ahlmen M, et al.; BARFOT Study Group. Sex: a major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis. 2007;66(1):46–52. DOI: http://dx.doi.org/10.1136/ard.2006.056937. Morgan C, Lunt M, Brightwell H, et al. Contribution of patient related differences to multidrug resistance in rheumatoid arthritis. Ann Rheum Dis. 2003;62(1):15–9. DOI: http://dx.doi.org/10.1136/ard.62.1.15. Hider SL, Silman AJ, Thomson W, et al. Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis? Ann Rheum Dis. 2009;68(1):57–62. DOI:10.1136/ard.2008.088237. Saevarsdottir S, Wallin H, Seddighzadeh M, et al.; SWEFOT Trial Investigators Group. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase ofthe SWEFOT trial. Ann Rheum Dis. 2011;70(3):469–75. DOI:10.1136/ard.2010.139212. Vazquez I, Graell E, Gratacos J, et al. Prognostic markers of clinical remission in early rheumatoid arthritis after two years of DMARDs in a clinical setting. Clin Exp Rheumatol. 2007;25(2):231–8. Ma MH, Ibrahim F, Walker D, et al. Remission in early rheumatoid arthritis: predicting treatment response. J Rheumatol. 2012;39(3):470–5. DOI:10.3899/jrheum.110169. Mottonen T, Hannonen P, Korpela M, et al.; FIN-RACo Trial Group. FINnish Rheumatoid Arthritis Combination therapy. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum. 2002;46(4):894–8. DOI: http://dx.doi.org/10.1002/art.10135. Combe B, Cantagrel A, Goupille P, et al. Predictive factors of 5-year health assessment questionnaire disability in early rheumatoid arthritis. J Rheumatol. 2003;30(11):2344–9. Hodkinson B, Musenge E, Ally M, et al. Response to traditional disease-modifying anti-rheumatic drugs in indigent South Africans with early rheumatoid arthritis. Clin Rheumatol. 2011;31(4):613–9. DOI:10.1007/s10067-011-1900-5. Cao Y, Bonner A, Barra LJ. Response to second-line DMARDs and TNFi in seropositive and seronegative patientsin early and late rheumatoid arthritis are not the same: results from the CATCH cohort and a large, established rheumatoid arthritis database [abstract]. Arthritis Rheum. 2011;63 Suppl 10):2202. Verschueren P, Esselens G, Westhovens R. Predictors of remission, normalized physical function, and changes in the working situation during follow-up of patients with early rheumatoid arthritis: an observational study. Scand J Rheumatol. 2009;38(3):166–72. DOI: http://dx.doi.org/10.1080/03009740802484846. Wessels JA, van der Kooij SM, le Cessie S, et al; Pharmacogenetics Collaborative Research Group. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 2007;56(6):1765–75. DOI: http://dx.doi.org/10.1002/art.22640. Mori S, Hirose J, Yonemura K. Contribution of HLA-DRB1*04 alleles and anti-cyclic citrullinated antibodies to development of resistance to disease-modifying antirheumatic drugs in early rheumatoid arthritis. Clin Rheumatol. 2010;29(12):1357–66. DOI:10.1007/s10067-010-1454-y. Knowlton N, Jiang K, Frank MB, et al. The meaning of clinical remission in polyarticular juvenile idiopathic arthritis: gene expression profiling in peripheral blood mononuclear cells identifies distinct disease states. Arthritis Rheum. 2009;60(3):892–900. DOI:10.1002/art.24298.

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/1348
https://doi.org/10.14412/1995-4484-2013-654-61

RITUXIMAB THERAPY MONITORING IN PATIENTS WITH RHEUMATOID ARTHRITIS HROUGH PERIPHERAL BLOOD GENE EXPRESSION ANALYSIS ; Мониторинг терапии ритуксимабом больных ревматоидным артритом посредством анализа экспрессии генов в периферической крови

Συγγραφείς: E. V. Chetina, A. V. Pivanova, K. Kh. Kuzikyants, A. Yu. Devyataikina, G. V. Lukina, E. Yu. Samarkina, A. P. Aleksankin, E. N. Aleksandrova, Е. В. Четина, А. В. Пиванова, К. Х. Кузикянц, А. Ю. Девятайкина, Г. В. Лукина, Е. Ю. Самаркина, А. П. Алексанкин, Е. Н. Александрова

Πηγή: Rheumatology Science and Practice; Vol 52, No 3 (2014); 263-269 ; Научно-практическая ревматология; Vol 52, No 3 (2014); 263-269 ; 1995-4492 ; 1995-4484 ; 10.14412/rjtao20143

Θεματικοί όροι: ритуксимаб, gene expression, peripheral blood, inflammation, joint lesion, rituximab, экспрессия генов, периферическая кровь, воспаление, поражение суставов

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/1937/1209; Насонов ЕЛ. Применение ритуксимаба при ревматоидном артрите. В кн.: Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Под ред. Е.Л. Насонова. Москва: ИМА-ПРЕСС; 2012. С. 55–93. [Nasonov EL. Application rituk- simab at rheumatoid arthritis. In: Anti-B-kletochnaya terapiya v revmatologii: fokus na rituksimab [Anti-B-cellular therapy in rheumatology: focus on rituksimab]. Nasonov EL, editor. Moscow: IMA-PRESS; 2012. P. 55–93.]; Tuscano JM, Sands J. B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis. Biologics. 2009;3:225–32. Epub 2009 Jul 13. DOI: http://dx.doi.org/10.2147/BTT.S3168.; Chan OT, Madaio MP, Shlomchik MJ. The central and multiple roles of B cells in lupus pathogenesis. Immunological Reviews. 1999;169:107–21. DOI: http://dx.doi.org/10.1111/j.1600- 065X.1999.tb01310.x.; Lund FE. Cytokine-producing B lymphocytes – key regulators of immunity. Currt Opin Immunol. 2008;20:332–8. DOI: http://dx.doi.org/10.1016/j.coi.2008.03.003. Epub 2008 Apr 15.; Fillatreau S, Gray D, Anderton SM. Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol. 2008;8(5):391–7. DOI:10.1038/nri2315.; Fillatreau S, Sweenie CH, McGeachy MJ, et al. B cells regulate autoimmunity by provision of IL-10. Nat Immunol. 2002;3(10):944–50. DOI: http://dx.doi.org/10.1038/ni833. Epub 2002 Sep 3.; Reichardt P, Dornbach B, Rong S, et al. Naive B cells generate regulatory T cells in the presence of a mature immunologic synapse. Blood. 2007;110(5):1519–29. DOI: http://dx.doi.org/10.1182/blood-2006-10-053793. Epub 2007 Mar 28.; Anolik JH, Looney RJ, Lund FE, et al. Insights into the hetero- geneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res. 2009 Dec;45(2–3):144–58. DOI:10.1007/s12026-009-8096-7.; Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2):435–45.; Anderson KC, Bates MP, Slaughenhoupt BL, et al. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood. 1984;63(6):1424–33.; Martin F, Chan AC. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol. 2006;24:467–96. DOI: http://dx.doi.org/10.1146/annurev.immunol.24.021605.090517.; Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor thera- py: results of a multicenter, randomized, double-blind, placebo- controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793–806. DOI: http://dx.doi.org/10.1002/art.22025.; Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthri- tis. N Engl J Med. 2004;350(25):2572–81. DOI: http://dx.doi.org/10.1056/NEJMoa032534.; Keystone EC, Emery P, Peterfy CG, et al. Rituximab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis. 2009;68(2):216–21. DOI:10.1136/ard.2007.085787. Epub 2008 Apr 3.; Thurlings RM, Vos K, Wijbrandts CA, et al. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis. 2008;67(7):917–25. DOI: http://dx.doi.org/10.1136/ard.2007.080960. Epub 2007 Oct 26.; Ferraro AJ, Drayson MT, Savage CO, MacLennan IC. Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with rituximab. Eur J Immunol. 2008;38(1):292–8. DOI: http://dx.doi.org/10.1002/eji.200737557.; Cambridge G, Leandro MJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 2003;48(8):2146–54. DOI: http://dx.doi.org/10.1002/art.11181.; Dass S, Rawstron A, Vital E, et al. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 2008;58(10):2993–9. DOI: http://dx.doi.org/10.1002/art.23902.; Higashida J, Wun T, Schmidt S, et al. Safety and efficacy of ritux- imab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor alpha treatment. J Rheumatol. 2005;32(11):2109–15.; Julia A, Barcelo M, Erra A, et al. Identification of candidate genes for rituximab response in rheumatoid arthritis patients by microar- ray expression profiling in blood cells. Pharmacogenomics. 2009 Oct;10(10):1697–708. DOI:10.2217/pgs.09.99.; Rosengren S, Wei N, Kalunian KC, et al. CXCL13: a novel bio- marker of B-cell return following rituximab treatment and synovi- tis in patients with rheumatoid arthritis. Rheumatology (Oxford). 2011 Mar;50(3):603–10. DOI:10.1093/rheumatology/keq337. Epub 2010 Nov 23.; Maloney DG, Smith B, Appelbaum FR. The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct antiproliferative activity and induction of apoptosis in CD20 posi- tive non-Hodgkin’s lymphoma (NHL) cell lines. Blood. 1996;88 (Suppl 1):637.; Van Meerten T, van Rijn RS, Hol S, et al. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res. 2006;12(13):4027–35. DOI: http://dx.doi.org/10.1158/1078-0432.CCR-06-0066.; Raterman HG, Vosslamber S, de Ridder S, et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther. 2012 Apr 27;14(2):R95. DOI:10.1186/ar3819.; Hogan VE, Holweg CT, Choy DF, et al. Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximab. Ann Rheum Dis. 2012 Nov;71(11):1888–94. DOI:10.1136/annrheumdis-2011-201115.; Gutierrez-Roelens I, Galant C, Theate I, et al. Rituximab treat- ment induces the expression of genes involved in healing processes in the rheumatoid arthritis synovium. Arthritis Rheum. 2011 May;63(5):1246–54. DOI:10.1002/art.30292.; Vosslamber S, Raterman HG, van der Pouw Kraan TC, et al. Pharmacological induction of IFN type I activity following thera- py with rituximab determines clinical response in rheumatoid arthritis. Ann Rheum Dis. 2011;70:1153–9. DOI:10.1136/ard.2010.147199. Epub 2011 Mar 27.; Tchetina ЕV, Demidova NV, Semyonova LA, et al. Differential expression of mammalian target of rapamycin (mTOR) in the peripheral blood of early-stage rheumatoid arthritis patients as a prognostic marker of the disease activity and knee joint destruc- tion: a two year follow-up study. Ann Rheum Dis. 2010;69 Suppl 3:675.; Четина ЕВ, Демидова НВ, Каратеев ДЕ, Насонов ЕЛ. Гетерогенность первичных больных ревматоидным артритом по экспрессии генов в крови: теоретические основы дифференциального подхода к терапии. Научно- практическая ревматология. 2011;49(4):24–30. [Chetina EV, Demidova NV, Karateev DE, Nasovov EL. Heterogeneity of early rheumatoid arthritis patients according to blood gene expression: theoretical bases of a differential therapy approach. Nauchno- prakticheskaya revmatologiya = Rheumatology Science and Practice. 2011;49(4):24–30. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2011-57.; Четина ЕВ, Семенова ЛА, Логунов АЛ и др. Повышенная экспрессия регуляторных генов в крови и суставном хряще больных ревматоидным артритом. Научно-практическая ревматология. 2012;50(4):44–8. [Chetina EV, Semyonova LA, Logunov AL, et al. Enhanced regulatory gene expressions in the blood and articular cartilage of patients with rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;50(4):44–8. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2012-1111.; Tchetina EV, Demidova NV, Karateev DE, Nasonov EL. Rheumatoid factor positivity is associated with increased joint destruction and upregulation of matrix metalloproteinase 9 and cathepsin K gene expression in the peripheral blood in rheumatoid arthritis patients treated with methotrexate. Int J Rheumatol. 2013;2013:457876. DOI: http://dx.doi.org/10.1155/2013/457876. Epub 2013 Nov 14.; Четина ЕВ, Демидова НВ, Каратеев ДЕ, Насонов ЕЛ. Регистрация изменения экспрессии генов в крови как дополнительный инструмент мониторинга терапии метотрексатом больных ревматоидным артритом. Научно- практическая ревматология. 2013;51(6):654–61. [Chetina EV, Demidova NV, Karateev DE, Nasonov EL. Analysis of gene expression in blood as an additional tool to monitor methotrexate therapy in patients with rheumatoid arthritis. Nauchno-praktich- eskaya revmatologiya = Rheumatology Science and Practice. 2013;51(6):654–61. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2013-654-61.; Четина ЕВ, ДиБатиста Д, Пул АР. Роль простагландина E2 в ингибировании разрушения коллагена суставного хряща больных остеоартрозом. Научно-практическая ревматология. 2009;48(3):18–24. [Chetina EV, DiBattista D, Pool AR. Prostaglandin E2 role in inhibition of joint cartilage collagen destruction in patients with osteoarthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2009;48(3):18–24. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2009-1308.; Tchetina EV, Poole AR, Zaitseva EM, et al. Differences in mTOR (mammalian target of rapamycin) gene expression in the peripher- al blood and articular cartilages of osteoarthritic patients and dis- ease activity. Arthritis. 2013:2013:461486. DOI:10.1155/2013/461486. Epub 2013 Jun 25.; Verweij CL, Vosslamber S. New insight in the mechanism of action of rituximab: the interferon signature towards personalized medi- cine. Discov Med. 2011 Sep;12(64):229–36.; Troen BR. The role of cathepsin K in normal bone resorption. Drug News Perspect. 2004;17(1):19–28. DOI: http://dx.doi.org/10.1358/dnp.2004.17.1.829022.; Kawasaki Y, Xu ZZ, Wang X, et al. Distinct roles of matrix metal- loproteases in the early- and late-phase development of neuro- pathic pain. COX2 in CNS neural cells mediates mechanical inflammatory pain hypersensitivity in mice. Nat Med. 2008 Mar;14(3):331–6. DOI:10.1038/nm1723. Epub 2008 Feb 10.; Vardeh D, Wang D, Costigan M, et al. COX2 in CNS neural cells mediates mechanical inflammatory pain hypersensitivity in mice. J Clin Invest. 2009 Feb;119(2):287–94. DOI:10.1172/JCI37098. Epub 2009 Jan 5.

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/1937
https://doi.org/10.14412/1995-4484-2014-263-269

Узловатая эритема при синдроме Лефгрена

Πηγή: Клиницист.

Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, САРКОИДОЗ,СИНДРОМ ЛЕФГРЕНА,УЗЛОВАТАЯ ЭРИТЕМА,ПОРАЖЕНИЕ СУСТАВОВ,ГРАНУЛЕМАТОЗНОЕ ВОСПАЛЕНИЕ,ПАННИКУЛИТ,КОМПЬЮТЕРНАЯ ТОМОГРАФИЯ,ВНУТРИГРУДНАЯ ЛИМФАДЕНОПАТИЯ,ФЕНОМЕН 'МАТОВОГО СТЕКЛА',ДИАГНОСТИКА,ФАРМАКОТЕРАПИЯ, 3. Good health

Περιγραφή αρχείου: text/html

Σύνδεσμος πρόσβασης: http://cyberleninka.ru/article_covers/16869979.png
http://cyberleninka.ru/article/n/uzlovataya-eritema-pri-sindrome-lefgrena

Whipple’s disease ; Болезнь Уиппла

Συγγραφείς: Boris Sergeyevich Belov, Б. С. Белов

Πηγή: Modern Rheumatology Journal; Том 7, № 1 (2013); 12-17 ; Современная ревматология; Том 7, № 1 (2013); 12-17 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2013-1

Θεματικοί όροι: антибиотикотерапия, Whipple’s disease, Tropheryma whipplei, joint lesion, endocarditis, antibiotic therapy, поражение суставов, эндокардит

Περιγραφή αρχείου: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/459/437

Διαθεσιμότητα: https://mrj.ima-press.net/mrj/article/view/459
https://doi.org/10.14412/1996-7012-2013-2361

БОЛЕЗНЬ УИППЛА

Συγγραφείς: Белов, Борис

Θεματικοί όροι: БОЛЕЗНЬ УИППЛА, ПОРАЖЕНИЕ СУСТАВОВ, ЭНДОКАРДИТ, АНТИБИОТИКОТЕРАПИЯ, WHIPPLE’S DISEASE

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/bolezn-uippla
http://cyberleninka.ru/article_covers/14419444.png

АНАЛИЗ ЭКСПРЕССИИ ГЕНОВ В КРОВИ КАК ДОПОЛНИТЕЛЬНЫЙ ИНСТРУМЕНТ МОНИТОРИНГА ТЕРАПИИ МЕТОТРЕКСАТОМ БОЛЬНЫХ РЕВМАТОИДНЫМ АРТРИТОМ

Συγγραφείς: Четина, Елена, Демидова, Н., Каратеев, Д., Насонов, Е.

Θεματικοί όροι: РЕВМАТОИДНЫЙ АРТРИТ, ЭКСПРЕССИЯ ГЕНОВ, ПЕРИФЕРИЧЕСКАЯ КРОВЬ, ВОСПАЛЕНИЕ, ПОРАЖЕНИЕ СУСТАВОВ, МЕТОТРЕКСАТ

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/analiz-ekspressii-genov-v-krovi-kak-dopolnitelnyy-instrument-monitoringa-terapii-metotreksatom-bolnyh-revmatoidnym-artritom
http://cyberleninka.ru/article_covers/15528824.png

HETEROGENEITY OF EARLY RHEUMATOID ARTHRITIS PATIENTS ACCORDING TO BLOOD GENE EXPRESSION: THEORETICAL BASES OF A DIFFERENTIAL THERAPY APPROACH ; ГЕТЕРОГЕННОСТЬ ПЕРВИЧНЫХ БОЛЬНЫХ РЕВМАТОИДНЫМАРТРИТОМ ПО ЭКСПРЕССИИ ГЕНОВ В КРОВИ: ТЕОРЕТИЧЕСКИЕ ОСНОВЫ ДИФФЕРЕНЦИАЛЬНОГО ПОДХОДАК ТЕРАПИИ

Συγγραφείς: E V Chetina, N V Demidova, D E Karateev, E L Nasovov, Н. В. Демидова, Дмитрий Евгеньевич Каратеев

Πηγή: Rheumatology Science and Practice; Vol 49, No 4 (2011); 24-30 ; Научно-практическая ревматология; Vol 49, No 4 (2011); 24-30 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2011-4

Θεματικοί όροι: поражение суставов, gene expression, peripheral blood, nflammation, joint degradation, экспрессия генов, периферическая кровь, воспаление

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/341/195; Firenstein G.S. Evolving concepts of rheumatoid arthritis. Nature 2003; 423:356-61. Rindfleisch J.A., Muller D. Diagnosis and management of rheumatoid arthritis. Am Fam Physician 2005;72:1037-47. Karp G. Cell and molecular biology: concepts and experiments. 4th ed. Hoboken, NJ: John Wiley and Sons, 2005;598-9. Blagosklonny M.V. Cell senescence and hypermitogenic arrest. EMBO Report 2003;4:358-62. Demidenko Z.N., Blagosklonny M.V. Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle 2008;7:3355-61. Eguchi K. Apoptosis in autoimmune diseases. Intern Med 2001;40:275-84 Lum J.J., DeBerardinis R.J., Thompson C.B. Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol 2005;6:439-48. Levine B., Klionsky D.J. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 2004;6:463-77. Hay N., Sonnenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-45 Четина Е.В., ДиБатиста Д., Пул А.Р. Роль простагландина E2 в ингибировании разрушения коллагена суставного хряща больных остеоартрозом. Науч-практич ревматол 2009;3:18-23. Насонов Е.Л., Самсонов М.Ю. Новые направления в исследовании воспаления при ревматических заболеваниях. Избранные лекции по клинической ревматологии. Под ред. В.А. Насоновой, Н.В. Бунчука. М., 2001;29-44. Proud C.G. Regulation of mammalian translation factors by nutrients. Eur J Biochem 2002;269:5338-42. Laviano A., Meguid M.M., Inui A. et al. Role of leucine in regulating food intake. Science 2006;313:1236- Westwood O.M.R., Nelson P.N., Hay F.C. Rheumatoid factors: what's new? Rheumatology 2006;45:379-85. Garner E., Raj K. Protective mechanisms of p53-p21-pRb proteins against DNA damage-induced cell death. Cell Cycle 2008;7:277-82. Karouzakis E., Neidhart M., Gay R.E., Gay S. Molecular and cellular basis of rheumatoid joint destruction. Immunol Letters 2006;106:8-13. Van Oosterhout M., Bajema I., Levarht E.W. et al. Differences in synovial tissue infiltrates between anti-cyclic citrullinated peptidepositive rheumatoid arthritis and anti-cyclic citrullinated peptide-negative rheumatoid arthritis. Arthr Rheum 2008;58:53-60. Knowlton N., Jiang K., Frank M.B. et al. The meaning of clinical remission in polyarticular juvenile idiopathic arthritis: gene expression profiling in peripheral blood mononu-clear cells identifies distinct disease states. Arthr Rheum 2009;60:892-900.

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/341
https://doi.org/10.14412/1995-4484-2011-57

ГЕТЕРОГЕННОСТЬ ПЕРВИЧНЫХ БОЛЬНЫХ РЕВМАТОИДНЫМ АРТРИТОМ ПО ЭКСПРЕССИИ ГЕНОВ В КРОВИ: ТЕОРЕТИЧЕСКИЕ ОСНОВЫ ДИФФЕРЕНЦИАЛЬНОГО ПОДХОДА К ТЕРАПИИ

Συγγραφείς: Четина, Е., Демидова, Н., Каратеев, Д., Насонов, Е.

Θεματικοί όροι: РЕВМАТОИДНЫЙ АРТРИТ, ЭКСПРЕССИЯ ГЕНОВ, ПЕРИФЕРИЧЕСКАЯ КРОВЬ, ВОСПАЛЕНИЕ, ПОРАЖЕНИЕ СУСТАВОВ

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/geterogennost-pervichnyh-bolnyh-revmatoidnym-artritom-po-ekspressii-genov-v-krovi-teoreticheskie-osnovy-differentsialnogo-podhoda-k
http://cyberleninka.ru/article_covers/14046494.png

ЭФФЕКТИВНОСТЬ ЭЛЕКТРОФОРЕЗА ГРЯЗИ ОЗЕРА «УЧУМ» ПРИ ЛОКОМОТОРНОЙ ФОРМЕ ХРОНИЧЕСКОГО БРУЦЕЛЛЕЗА

Συγγραφείς: Сергеева, И.

Θεματικοί όροι: ХРОНИЧЕСКИЙ БРУЦЕЛЛЕЗ, ПОРАЖЕНИЕ СУСТАВОВ, КЛИНИКО-ЛАБОРАТОРНЫЕ ДАННЫЕ, СУЛЬФИДНО-ИЛОВАЯ ГРЯЗЬ ОЗЕРА "УЧУМ"

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/effektivnost-elektroforeza-gryazi-ozera-uchum-pri-lokomotornoy-forme-hronicheskogo-brutselleza
http://cyberleninka.ru/article_covers/14519738.png

Мониторинг терапии ритуксимабом больных ревматоидным артритом посредством анализа экспрессии генов в периферической крови

Πηγή: Научно-практическая ревматология.

Θεματικοί όροι: РЕВМАТОИДНЫЙ АРТРИТ, ЭКСПРЕССИЯ ГЕНОВ, ПЕРИФЕРИЧЕСКАЯ КРОВЬ, ВОСПАЛЕНИЕ, ПОРАЖЕНИЕ СУСТАВОВ, РИТУКСИМАБ, 3. Good health

Περιγραφή αρχείου: text/html

Σύνδεσμος πρόσβασης: http://cyberleninka.ru/article_covers/15616068.png
http://cyberleninka.ru/article/n/monitoring-terapii-rituksimabom-bolnyh-revmatoidnym-artritom-posredstvom-analiza-ekspressii-genov-v-perifericheskoy-krovi